01/05/2019 12:00:00

uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in May:

  • 2019 American Academy of Neurology (AAN) Annual Meeting, May 4 – 10, Philadelphia, PA.

     

    • uniQure will deliver multiple data presentations at the meeting covering the Company’s advancements for its gene therapy candidates in Huntington’s disease and Spinocerebellar Ataxia Type 3.

       

  • Canaccord Genuity Gene Therapy Manufacturing Summit, May 9, Boston, MA.

     

    • Scott McMillan, chief operating officer at uniQure, will be presenting on Thursday May 9th at 10:00 a.m. ET, followed by the AAV Manufacturing panel discussion at 10:30 a.m. ET.

       

  • Hemostasis & Thrombosis Research Society 2019 Scientific Symposium, May 9 - 11, New Orleans, LA.

     

    • Adam Giermasz, M.D., Ph.D., investigator of the trial at UC Davis, CA, will present 26 weeks of follow-up data on the three patients in the AMT-061 Phase 2b study.

Title:

A Single Infusion of AMT-061 (AAV5-Padua hFIX) is Safe and Effective in Adults

with Hemophilia B: Interim Results from Dose-Confirmation Phase 2b Trial (#44)

Session:

Poster Session 1

Date & Time:

Friday, May 10, 4:45 – 5:55 p.m. CT

Location:

St. Charles Ballroom

  • Italian Association of Huntington’s Disease Roma 2019 Meeting, May 18, Rome, Italy.

     

    • Astrid Valles-Sanchez, senior scientist at uniQure will be presenting “Development of a microRNA-based gene therapy for Huntington’s disease” on Saturday, May 18th at 10:30 a.m. CET.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. www.uniQure.com

uniQure Contacts

For Investors:                                                                                                     

Maria E. Cantor                                                                              

Direct: 339-970-7536                                                          

Eva M. Mulder

Direct: +31 20 240 6103  

For Media:

Tom Malone

Direct:  339-970-7558

Logo-uniQure-MS-Word_Orange.jpg

Related content
06 Jul - 
uniQure Announces 36 Weeks of Follow-Up Data from Phase..
21 Jun - 
uniQure Announces Presentations at the Upcoming 27th Co..
31 May - 
uniQure to Participate in Multiple Upcoming Industry Co..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
CellaVision ABs strongest quarter ever with continued growth
2
Corporate Social Responsibility: Eramet commits to short-term specific objectives
3
Yara signs new USD 1,100 million Revolving Credit Facility with margin linked to Carbon Intensity Target
4
Arc Aroma Pure AB: 190716 ArcAroma and Källby wastewater treatment plant starts evaluation of dynaCEPT®
5
Change in the Board of Directors of Realkredit Danmark A/S

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 July 2019 02:25:46
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB4 - 2019-07-17 03:25:46 - 2019-07-17 02:25:46 - 1000 - Website: OKAY